Your browser doesn't support javascript.
Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.
Subbarao, Sathyavani; Warrener, Lenesha A; Hoschler, Katja; Perry, Keith R; Shute, Justin; Whitaker, Heather; O'Brien, Michelle; Baawuah, Frances; Moss, Paul; Parry, Helen; Ladhani, Shamez N; Ramsay, Mary E; Brown, Kevin E; Amirthalingam, Gayatri.
  • Subbarao S; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom.
  • Warrener LA; Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom.
  • Hoschler K; Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom.
  • Perry KR; Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom.
  • Shute J; Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom.
  • Whitaker H; Statistics, Modelling and Economics Department, National Infection Service, Public Health England, London, United Kingdom.
  • O'Brien M; Brondesbury Medical Centre, Kilburn, London, United Kingdom.
  • Baawuah F; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom.
  • Moss P; Brondesbury Medical Centre, Kilburn, London, United Kingdom.
  • Parry H; Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom.
  • Ladhani SN; Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom.
  • Ramsay ME; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom.
  • Brown KE; Paediatric Infectious Diseases Research Group, St. George's University of London, London, United Kingdom.
  • Amirthalingam G; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom.
Euro Surveill ; 26(12)2021 03.
Article in English | MEDLINE | ID: covidwho-1154193
ABSTRACT
Sera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in > 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom's approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 / Antibodies, Viral / Antibody Formation Type of study: Experimental Studies / Observational study Topics: Vaccines Limits: Aged / Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 1560-7917.ES.2021.26.12.2100329

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 / Antibodies, Viral / Antibody Formation Type of study: Experimental Studies / Observational study Topics: Vaccines Limits: Aged / Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 1560-7917.ES.2021.26.12.2100329